OpenAI LifeSciBench: 750 Tasks for Life Sciences AI

OpenAI Just Built Its Own Life Sciences Exam

OpenAI announced LifeSciBench on June 17, 2026 — a new benchmark purpose-built for evaluating AI across real-world life sciences workflows. It's not another multiple-choice knowledge quiz. LifeSciBench comprises 750 tasks across seven distinct scientific workflows, scored by domain experts rather than automated metrics. And the headline result: GPT-Rosalind, OpenAI's life-sciences-specialized model, outperforms GPT-5.5 across the board.

The announcement arrived alongside new capabilities for GPT-Rosalind (per OpenAI's official blog post), and signals something broader about where OpenAI sees the next high-value frontier for AI deployment: not just chatbots and code, but the workflows that drive drug discovery, genomics, and clinical research.

What LifeSciBench Actually Measures

Most AI benchmarks in the sciences test factual recall — the equivalent of a biology pop quiz. LifeSciBench takes a different approach by structuring its 750 tasks around seven real-world life sciences workflows, according to OpenAI's announcement.

OpenAI hasn't published the full taxonomy of those seven workflows at the time of writing, but based on GPT-Rosalind's known capabilities and the "real-world" framing, these likely span areas such as:

• Literature synthesis — pulling insights across papers, patents, and clinical trial databases
• Molecular analysis — interpreting protein structures, binding affinities, or sequence data
• Experimental design — suggesting protocols, controls, and statistical frameworks
• Data interpretation — reading assay results, imaging data, or omics outputs
• Regulatory and clinical reasoning — navigating FDA pathways, adverse event analysis, trial endpoint design

The key differentiator: expert judging. Rather than checking answers against a fixed key, LifeSciBench uses domain experts — scientists who evaluate whether the AI's output would actually be useful in a professional context. That's a meaningful design choice. Automated benchmarks reward pattern-matching. Expert evaluation rewards the kind of nuanced, context-dependent reasoning that matters when the output feeds into a drug development pipeline or a clinical decision.

GPT-Rosalind vs. GPT-5.5: Why the Specialist Wins

The headline result from OpenAI's announcement is that GPT-Rosalind outperforms GPT-5.5 on LifeSciBench. OpenAI hasn't published granular per-workflow scores publicly (as of this writing), but the directional finding is significant on its own.

GPT-5.5 is OpenAI's flagship general-purpose model — broadly excellent across coding, reasoning, creative writing, and general knowledge. The fact that a domain-specialized model beats it on a domain-specific benchmark isn't shocking in isolation. What's notable is that OpenAI chose to build, benchmark, and publicize this gap. That's a strategic statement: general-purpose models aren't enough for high-stakes scientific work.

My read: This is OpenAI telling pharma and biotech that they need GPT-Rosalind, not just ChatGPT with a science prompt. The benchmark exists to create a buying reason for the specialized product.

That's not a criticism — it's how the industry works. Google did the same with Med-PaLM and its medical benchmarks. Specialized models need specialized benchmarks to demonstrate their value. LifeSciBench is GPT-Rosalind's proof point.

Why Expert-Judged Benchmarks Matter More Than You Think

The shift toward expert-judged evaluation is arguably more important than the specific results. Here's why.

Traditional AI benchmarks — MMLU, HumanEval, GSM8K — measure whether a model gets the "right answer." That works for math problems and code that either compiles or doesn't. It fails badly for scientific work, where:

• Multiple valid approaches exist for the same problem
• The quality of reasoning matters as much as the final answer
• Context and caveats are critical (a drug interaction analysis that's technically correct but misses a key contraindication is worse than useless)
• Real-world utility depends on how the output integrates into existing workflows

Expert judging addresses these gaps. It's also far more expensive and harder to scale, which is why most benchmarks don't do it. OpenAI investing in 750 expert-evaluated tasks suggests they're serious about the life sciences vertical, not just testing the waters.

The Benchmark Credibility Question

There's an obvious tension here: OpenAI built the benchmark, and OpenAI's model tops it. That's the same "we grade our own homework" dynamic that has plagued AI benchmarks since GPT-4's launch. A few things to watch for:

• Will OpenAI open-source LifeSciBench? If third parties can run their models against it — Google's Gemini, Anthropic's Claude, open models like BioMistral — the benchmark gains credibility. If it stays proprietary, it's marketing material dressed as science.
• Who are the expert judges? Their affiliations, conflict-of-interest disclosures, and the inter-rater reliability scores matter enormously. OpenAI hasn't disclosed these details yet.
• Is the task set representative? 750 tasks across seven workflows is a reasonable starting size, but life sciences is vast. Whether LifeSciBench covers the workflows that matter to actual pharma R&D teams is an open question.

None of this means LifeSciBench is illegitimate — just that independent validation is the difference between a benchmark and a press release.

The Bigger Picture: Vertical AI Models Are the Play

LifeSciBench and GPT-Rosalind fit into a clear industry pattern. The era of "one model to rule them all" is giving way to specialized vertical models with domain-specific training, evaluation, and go-to-market strategies.

Company	Vertical Model	Domain	Custom Benchmark
OpenAI	GPT-Rosalind	Life Sciences	LifeSciBench (750 tasks, expert-judged)
Google	Med-PaLM 2	Medicine	MultiMedQA, MedQA
Google	AlphaFold 3	Protein Structure	CASP targets
Anthropic	Claude (w/ Glasswing)	Cybersecurity	Internal vuln discovery metrics

The playbook is consistent: build a specialized model, create or adopt a benchmark that highlights its strengths, then sell into the vertical. For life sciences specifically, the stakes are high — pharma companies spend billions on R&D, and even marginal improvements in literature review speed, target identification, or trial design translate to real money.

What This Means for Scientists and Pharma Teams

If you're in biotech, pharma, or academic life sciences, here's what's actually actionable:

GPT-Rosalind is worth evaluating on your specific workflows. Benchmark scores — even expert-judged ones — don't tell you how a model performs on your data, with your constraints. The LifeSciBench result suggests GPT-Rosalind has been meaningfully fine-tuned for scientific reasoning, but your mileage will depend on whether its training distribution matches your domain (structural biology vs. clinical pharmacology vs. epidemiology are very different beasts).

Don't assume GPT-5.5 is automatically worse for your use case. GPT-Rosalind outperforms on LifeSciBench's aggregate, but general-purpose models sometimes win on tasks that require broad reasoning across domains — like connecting a genomics finding to a regulatory strategy. Specialization has tradeoffs.

Watch for independent LifeSciBench results. If and when other model providers run against LifeSciBench, that data will be far more useful than OpenAI's self-reported numbers. Keep an eye on whether Hugging Face, Papers with Code, or academic groups pick this up.

Open Questions

Several things OpenAI hasn't disclosed yet that would sharpen the picture:

• Granular per-workflow scores: Does GPT-Rosalind win all seven workflows, or dominate some while being marginal on others?
• Comparison to non-OpenAI models: How does Claude, Gemini, or open-source alternatives like BioMistral perform on the same 750 tasks?
• Pricing and access: GPT-Rosalind's availability and cost structure for API users and enterprise pharma clients hasn't been fully detailed alongside this announcement.
• Training data transparency: What scientific corpora was GPT-Rosalind fine-tuned on? This matters for reproducing results and understanding potential biases.
• Expert judge methodology: Rubrics, inter-rater agreement, and judge selection criteria would help assess whether the 750-task evaluation is rigorous or hand-picked.

The Honest Take

LifeSciBench is a smart move by OpenAI. It creates a quantitative story for GPT-Rosalind in a market — pharma and biotech — where quantitative evidence is the price of admission. Expert judging is the right methodology for scientific work, even if it's harder to scale than automated evals. And GPT-Rosalind beating GPT-5.5 is a genuine signal that domain specialization adds value beyond what prompt engineering on a general model can achieve.

But this is chapter one. The benchmark's credibility depends on whether it becomes an open standard or stays an OpenAI marketing asset. The life sciences AI space is moving fast — Google's AlphaFold line, Isomorphic Labs' $2.1 billion raise, and a growing ecosystem of biotech-native AI startups all represent alternative approaches. LifeSciBench is OpenAI planting its flag. Whether it becomes the industry's yardstick or just another internal eval depends entirely on what happens next.